Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173]
aState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China
bBiomedical Translational Research Institute, Jinan University, Guangzhou 510632, China
cState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen 361102, China
dSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
eDepartment of Pathology and Institute of Precision Medicine, Jining Medical University, Jining 272067, China
fDepartment of Pathology, Medical School, Dalian University, Dalian 116622, China
gDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421001, China
hSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China
iInstitute of Biomedical Sciences, Shandong Provincial Key Laboratory of Animal Resistance Biology, Collaborative Innovation Center of Cell Biology in Universities of Shandong, College of Life Sciences, Shandong Normal University, Jinan 250014, China
jNational Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004 China
kState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
lDepartment of Colorectal Surgery, Tianjin Union Medical Center, Nankai University, Tianjin 300121, China
* Corresponding authors.
收起